To further study the biological effects, as well as molecular mechanisms of CD24 associated sorafenib-resistance, we established two HCC cell lines by long-term exposure to sorafenib at low doses (0.625 μM) escalating to higher doses, up to the cell surviving in medium with 10 μM (the highest clinically achievable concentration) sorafenib concentration (Supplementary Figure 1A). Here, CD24 is linked to hepatocellular carcinoma.